Product
Tusamitamab ravtansine
2 clinical trials
3 indications
Indication
TumorIndication
Gastric AdenocarcinomaIndication
Gastroesophageal CancerClinical trial
Open-label Study Evaluating the Effect of Tusamitamab Ravtansine on the QTc Interval in Participants With Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2023-08-01
Clinical trial
Open-label Study of Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Participants Previously Treated for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma With CEACAM5-positive TumorsStatus: Active (not recruiting), Estimated PCD: 2023-06-23